lupus. An unanswered question is whether an altered repertoire of T cell antigen receptors (TCRs) is associated with such expansion. Here we found that the transcription factor Blimp-1 (encoded by Prdm1) repressed expression of the gene encoding cathepsin S (Ctss), a cysteine protease that cleaves invariant chains and produces antigenic peptides for loading onto major histocompatibility complex (MHC) class II molecules. The increased CTSS expression in dendritic cells (DCs) from female mice with dendritic cell-specific conditional knockout of Prdm1 (CKO mice) altered the presentation of antigen to CD4 + T cells. Analysis of complementarity-determining region 3 (CDR3) regions containing the b-chain variable region (V b ) demonstrated a more diverse repertoire of T FH cells from female CKO mice than of those from wild-type mice. In vivo treatment of CKO mice with a CTSS inhibitor abolished the lupus-related phenotype and reduced the diversity of the T FH cell TCR repertoire. Thus, Blimp-1 deficiency in DCs led to loss of appropriate regulation of Ctss expression in female mice and thereby modulated antigen presentation and the T FH cell repertoire to contribute to autoimmunity.
The TCR repertoire is determined through positive and negative selection of T cells on the basis of recognition by the TCR of complexes of peptide and major histocompatibility complex (MHC) molecules presented by antigen-presenting cells (APCs). In the periphery, CD11c hi classical dendritic cells (cDCs) are the main APCs, with a critical role in both innate immune responses and adaptive immune responses 1, 2 . DCs activate natural killer cells, natural killer T cells and innate lymphocytes at the site of infection or sterile inflammation. They also process antigens and migrate to local lymphoid organs, where they activate naive T cells 3 . T cells require signals from a peptide-MHC class II complex, co-stimulatory molecules and cytokines provided by DCs for differentiation into various subsets of CD4 + effector T cells or CD4 + regulatory T cells (T reg cells), with each CD4 + effector T cell subset executing unique functions and secreting different cytokines 4 .
The cytokine milieu is critical for the differentiation of CD4 + T cells. Dominant cytokines help to establish the initial polarization of CD4 + helper T cell subsets: interleukin 12 (IL-12) establishes the T H 1 subset; IL-4 establishes the T H 2 subset; IL-6 and TGF-β establish the T H 17 subset; IL-6 establishes the T FH cell subset; and TGF-β and IL-10 establish the T reg cell subset. The differentiation of CD4 + T cells can be modulated by several other factors, such as the type of antigen and dose of exposure, affinity of the TCR for the MHC class II complex, and duration of stimulation 5, 6 .
The antigen-processing pathways in mouse DCs have been investigated extensively. After being taken up, antigens are transported into the endolysosomal compartment, where they are cleaved, and some of the fragments that are generated enter the groove of the MHC class II molecule for presentation to CD4 + T cells 7 . This process is dependent on the action of endocytic proteases in endosomal-lysosomal compartments 8 that fall into three main classes: cysteine proteases (cathepsins B, F, H, L, S and Z), aspartate proteases (cathepsins D and E) and serine proteases (cathepsins A and G). While all cathepsins can function in antigen processing and many show an overlapping expression pattern, CTSS has been shown to be expressed mainly in professional APCs, including B cells and DCs, in which it has a critical role in cleavage of the invariant chain to permit loading of peptides into MHC class II molecules 9 . CTSS also contributes to antigen processing through degradation of antigen in the endolysosome and helps to establish the pool of peptides that is available for presentation by MHC class II 10, 11 . Appropriate expression of CTSS is critical for establishment of the repertoire of immunocompetent cells. Modulation of the expression of cathepsins CTSS and CTSL can change the pool of peptides that are presented in vitro to CD4 + T cells 10 . Overexpression of CTSS in DCs and medullary epithelial cells in the thymus has been shown to permit autoreactive T cells to escape negative selection, presumably through too-exuberant degradation of autoantigens 12 . Whether negative regulation in the periphery is also affected by CTSS has not been addressed.
PRDM1, which encodes Blimp-1, was identified as a risk allele for systemic lupus erythematosus (SLE) in genome-wide association studies of Chinese Han and Northern European populations 13, 14 . CD14 + monocyte-derived DCs (MO-DCs) derived from carriers of the risk single-nucleotide polymorphism (SNP) (C/C) have lower expression of PRDM1 transcripts than do MO-DCs from carriers of the control (non-risk) SNP (T/T) 15 . To investigate the pathological function of Blimp-1 in SLE, we generated mice with DC-specific conditional knockout of Prdm1 (CKO mice) by mating mice expressing Cre recombinase from the gene encoding the integrin CD11c to mice with loxP-flanked Prdm1 alleles. Mice with loxP-flanked Prdm1 alleles but no expression of Cre recombinase served as the control (called 'wildtype' here). In female CKO mice, DCs that lacked Blimp-1 exhibited an activated phenotype with enhanced expression of MHC class II and increased production of pro-inflammatory cytokines following stimulation via Toll-like receptors. Those DCs resembled DCs from people with the SLE-associated PRDM1 risk allele, characterized by increased expression of MHC class II and hyper-responsiveness to stimulation via Toll-like receptors 15 . The frequency of T FH cells is greater in the blood of patients with lupus 16 , which correlates with disease activity 17, 18 . Female CKO mice have population expansion of T FH cells that is associated with a greater number of germinal center B cells that produce autoantibodies and cause antibody-mediated glomerulonephritis 19 . This phenotype is also critically dependent on greater production of IL-6 by Blimp-1-deficient DCs, as all autoimmune features are absent from female CKO Il6 +/− mice 19 . In the present study, we found that Blimp-1 also regulated Ctss expression in DCs and that Blimp-1-deficient splenic DCs and bone-marrow-derived DCs (BMDCs) exhibited higher expression of Ctss and alterations in antigen presentation, relative to that of wild-type DCs. These alterations led to a more-diverse TCR repertoire in the T FH cells of CKO mice. Finally, inhibition of CTSS in CKO mice suppressed development of the lupus-like phenotype and was associated with a lower number and diversity in the TCR repertoire of T FH cells.
RESULTS
Increased CTSS expression in Blimp-1-deficient DCs Blimp-1 has been suggested to participate in antigen presentation through downregulation of the gene encoding the MHC class II transactivator (Ciita) in B cells and CD11c + DCs 20, 21 . Consistent with those studies, in Blimp-1-deficient DCs have increased MHC class II expression 15 . To investigate whether Blimp-1 deficiency in DCs also leads to altered antigen processing, we assayed Blimp-1-deficient DCs from female C57BL/6 mice for expression of H2-Aa, Ciita, H2dmb, Ctss and other genes encoding products involved in antigen presentation. The expression of H2-Aa, Ciita, H2dmb and Ctss was significantly higher in Blimp-1-deficient DCs than wild-type DCs, whereas other genes showed no difference in expression (Fig. 1a) .
To investigate whether Blimp-1 can directly regulate the expression of mouse cathepsin-encoding genes, we searched for the Blimp-1 Data are from three independent experiments (a,b; n = 6 mice per genotype in a: horizontal bars, median; boxes, 25th percentile to 75th percentile; 'whiskers', 10th percentile and 90th percentile), two independent experiments (c), two independent experiments with n = 6 mice per group (d; plotted as in a), two independent experiments (e) or seven experiments with n = 19 female control carriers, n = 15 female risk carriers, n = 7 male control carriers and n = 11 male risk carriers (f; plotted as in a).
A r t i c l e s A r t i c l e s consensus core binding sequence (5′-GAAAGT-3′) in a region 1,500 base pairs upstream of the transcriptional start site of the first exon of each gene 22 Fig. 1b and Supplementary Fig. 1 ). Expression of Ctss was also higher in blood DCs of female CKO mice than in those of female wild-type mice (Fig. 1c) . To confirm that the increased expression of Ctss in DCs correlated with increased functional activity of CTSS, we assayed the enzymatic activity of CTSS in DCs purified from the spleen of female CKO and wild-type mice. We measured in vitro enzymatic activity by assaying fluorescence generated after cleavage of a CTSS substrate. Blimp-1-deficient DCs exhibited more catalytic activity than that of wild-type DCs (Fig. 1d) . Male CKO mice do not exhibit altered DC function and do not develop lupus-like disease 19 . Both the abundance of Ctss transcripts and the catalytic activity of CTSS were similar in DCs derived from male wild-type mice and those from male CKO mice (Fig. 1d,e) , which suggested that Blimp-1 deficiency in combination with sex-specific alterations in DCs altered Ctss expression. To address whether CTSS expression is associated with Blimp-1 expression in human MO-DCs, we measured CTSS expression in MO-DCs from the carriers of risk or control SNPs. MO-DCs from female carriers of the risk SNP exhibited lower PRDM1 expression, as reported 15 , and higher CTSS expression than that of MO-DCs from carriers of the non-risk SNP (Fig. 1f) .
Given the presence of a Blimp-1 consensus binding site within the Ctss promoter and the enhanced expression of CTSS in DCs of female CKO mice, we performed chromatin-immunoprecipitation (ChIP) assays to determine whether Blimp-1 bound to the Ctss promoter region in splenic CD11c + cDCs from wild-type mice. As expected, the Ctss promoter region was immunoprecipitated with antibody to Blimp-1 (Fig. 2a) , which indicated that Blimp-1 bound in vivo to the Ctss promoter in wild-type mice but not in CKO mice. To investigate whether binding by Blimp-1 negatively regulates the transcription of Ctss, we performed assays with a luciferase expression reporter driven by the Ctss promoter (positions −1300 to +10 relative to the transcription start site). There was significant suppression of luciferase expression when Blimp-1 was expressed (Fig. 2b) , which demonstrated that Blimp-1 downregulated activity of the Ctss promoter. Moreover, transfection of small interfering RNA (siRNA) specific for Prdm1 in wild-type DCs led to increased Ctss expression, but transfection of nonspecific (control) siRNA did not (Fig. 2c) , and restoration of Blimp-1 expression suppressed the abundance of Ctss transcripts and CTSS protein in Blimp-1-deficient DCs (Fig. 2d) . These data demonstrated that Ctss was a target of Blimp-1 in DCs 
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and that the binding of Blimp-1 to the promoter region of Ctss suppressed its transcription.
Sex specificity of altered Ctss expression
The differential expression of Ctss in Blimp-1-deficient DCs from male mice relative to that in such cells from female mice suggested the presence of additional regulators in the cells of female mice that contributed to Blimp-1-mediated Ctss regulation. DCs from female CKO mice exhibit higher expression of IL-6 following activation of Toll-like receptors than do their counterparts from female wild-type mice, while DCs from male CKO and wild-type mice exhibit similar IL-6 expression 19 . That observation is not unexpected, as IL-6 has been shown to be positively regulated by estrogen in BM-DCs 23 , a finding that we confirmed here ( Supplementary Fig. 2 ). The IL-6 signaling pathway activates the transcription activator and signal transducer STAT3, which is reported to be involved in the regulation of CTSS activity 24 We first sought to determine whether IL-6 exerted a direct effect on Ctss expression. Exogenous IL-6 enhanced the promoter activity of Ctss in BM-DCs, as assessed with the luciferase reporter construct described above ( Fig. 3a and Supplementary Fig. 3 ).
We also investigated whether STAT3 bound to the Ctss promoter. We identified a canonical consensus sequence for STAT3 binding, TTCCnGGAA (where 'n' indicates any nucleotide) 25 , at position −1118 (relative to the transcription start site), and three additional candidate binding sequences upstream of the transcription-initiation site of the Ctss 26 ( Fig. 3b) . We assessed the binding of STAT3 to each region by ChIP in wild-type BM-DCs. STAT3 bound at positions −1118 and −21 but not at position −2616 or −299 (Fig. 3b) , which suggested direct upregulation of Ctss by the IL-6-STAT3 signaling pathway in DCs. To confirm the binding of STAT3 to position −1118, we deleted this binding site in the Ctss promoter region of the luciferase construct. IL-6 did not enhance luciferase expression from the construct with the deletion of TTCCnGGAA, while it significantly enhanced luciferase expression from the construct with the intact Ctss promoter (Fig. 3b) .
To address the regulation of Ctss expression by IL-6 in vivo, we employed two approaches. First, we analyzed Ctss expression in DCs of female CKO mice that were haplosufficient for IL-6 (Il6 +/− ). Equivalent Ctss expression was observed in DCs from female CKO Il6 +/− mice and those from wild-type Il6 +/− mice (Fig. 3c) . We also administered neutralizing antibody to IL-6 (MP5-20F3) to female CKO mice. There was significantly lower Ctss expression in DCs from mice treated with neutralizing antibody than in those from mice treated with the control antibody immunoglobulin G (IgG) (Fig. 3c.  right) . Thus, IL-6 participated in the positive regulation of Ctss in DCs and probably contributed to the increased abundance of Ctss transcripts seen in Blimp-1-deficient DCs from female mice.
Blimp-1-deficient DCs 'preferentially' induce IL-21 + T cells
The greater number of T FH cells in female CKO mice might have resulted from skewed differentiation into T FH cells induced by Blimp-1-deficient DCs, as previously reported 19 , or from DC-induced changes in gene expression in T FH cells that led to enhanced survival of T FH cells in CKO mice. Irf4, Maf, Batf and Bcl6 encode transcription factors that positively influence the number of T FH cells 27 . We isolated T FH cells from female wild-type and CKO mice and assessed the expression of these genes. Only Bcl6 expression was significantly higher in T FH cells of female CKO mice than in those of female wildtype mice ( Supplementary Fig. 4) , which suggested the possibility of enhanced survival of T FH cells.
We reasoned that the higher expression of Ctss in Blimp-1-deficient DCs might affect antigen presentation by MHC class II molecules, which might influence the TCR repertoire in a manner favorable to the development of autoreactive T FH cells. We therefore assayed activation of OT-II CD4 + cells , which recognize a complex of ovalbumin (OVA) peptide (amino acids 323-339) and MHC class II. CD4 + T cells purified from OT-II mice were co-cultured for 3 d with CD11c + cDCs isolated from the spleen of female CKO or wild-type mice and either intact OVA protein or OVA peptide. T cell proliferation, measured as dilution of the division-tracking dye CFSE, was A r t i c l e s vigorous in the presence of each antigen preparation, regardless of the source of DCs (Fig. 4a) .
The activation of CD4 + T cells is characterized also by cytokine production. Splenic DCs pre-incubated with OVA protein were cultured with OT-II T cells, and the expression of cytokine-encoding mRNA by T cells and the frequency of T cells staining positive for cytokine protein were measured by qPCR and flow cytometry, respectively. Culture with Blimp-1-deficient DCs led to modestly but significantly greater IL-2 mRNA in the T cells than that of T cells cultured with wild-type DCs; however, the intracellular abundance of IL-2 in T cells cultured with Blimp-1-deficient DCs did not differ from that in T cells cultured with wild-type DCs (Fig. 4b,c) . The concentration of secreted IL-2 was also not different in these two culture conditions (Supplementary Fig. 5) , which explained the lack of difference in the proliferation index of T cells stimulated with wild-type DCs relative to that of T cells stimulated with Blimp-1-deficient DCs.
Many cytokines that are 'preferentially' expressed by T H 1, T H 2, T H 17 or T reg cells were not significantly different in cultures of T cells with Blimp-1-deficient DCs versus cultures of T cells wild-type DCs (Supplementary Fig. 6 ). While the expression of IL-21, produced by T FH cells , was relatively low compared with that of other cytokines, Il21 transcription and IL-21 production were greater in cultures with Blimp-1-deficient DCs and intact OVA than in cultures with wildtype DCs and intact OVA (Fig. 4b,c and Supplementary Fig. 5 ). Fig. 1a (right) ), twelve experiments (unfixed DCs) or ten experiments (fixed DCs) (b; plotted as in Fig. 1a) , or eight experiments (c, middle and right; plotted as in Fig. 1a) , are from one experiment representative of four (c, left) or three (d, top) independent experiments, or are from three experiments (d, bottom).
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The increased IL-21 was dependent on antigen processing, since it was abolished in cultures in which OVA peptide (amino acids 323-339) was used as the antigen (Supplementary Fig. 7) , and it was dependent on T cell-DC contact, as it was also abolished in Transwell cultures (Fig. 4b,c) . Fixation of DCs after incubation with OVA protein also revealed higher expression of IL-21 in cultures with Blimp-1-deficient DCs than in those with wild-type DCs, although IL-21 production by fixed DCs of each strain was less than that of unfixed cells (Fig. 4b) , presumably due to both the absence of cytokine secretion and the absence of membrane fluidity. The activation of OT-II T cells by OVA protein represented a cognate interaction between T cells and DCs, since the OT-II T cells were not activated with an irrelevant antigen (hen egg lysozyme) (Supplementary Fig. 8 ). To confirm that the enhanced activation of T cells mediated by Blimp-1-deficient DCs resulted from increased CTSS, we treated cultures with the CTSS inhibitor 219393 (with selectivity for CTSS ~400-fold greater than its selectivity for CTSB) 28 or with a CTSB inhibitor, as a control. When the CTSS inhibitor was added during OVA processing, there was no increased IL-21 production seen in cultures with Blimp-1-deficient DCs (Fig. 4b,c) , but when the CTSB inhibitor was added, that increase did occur (Supplementary Fig. 8 ).
To confirm that CTSS functions to alter antigen processing rather than antigen uptake, we incubated fluorescence (DQ)-conjugated OVA protein overnight with purified DCs from each strain and assessed OVA uptake by flow cytometry. There was no significant difference in the amoung of OVA internalized by wild-type DCs and that internalized by Blimp-1-deficient DCs (Fig. 4d) . These data suggested that the Blimp-1-deficient DCs had altered antigen processing. Thus, the increased CTSS altered antigen presentation, which induced activated CD4 + T cells to differentiate into T FH cells.
Diversity of the T FH cell TCR repertoire
To investigate whether the population expansion of T FH cells in CKO mice was accompanied by a change in their antigenic specificity, we compared the TCR repertoires of T FH cells in wild-type mice with those of CKO mice. T FH cells were purified from the spleens of young (6-10 weeks of age) female and male mice. T FH cells were identified by their expression of the chemokine receptor CXCR5 and costimulatory molecule PD-1; they also expressed the transcriptional repressor Bcl-6 (~95%) and costimulatory receptor ICOS-1 (~70%) (Fig. 5a) . Although no autoantibodies are detected at this age, there was already a greater number of T FH cells in female CKO mice than in wild-type mice (Fig. 5a) . We focused on V β sequences, as these are more diverse than V α sequences. We analyzed over 100,000 V β sequences in T FH cells from each of five female mice and five male mice of each strain. T FH cells from female CKO mice exhibited a more-diverse repertoire than that of T FH cells from female wild-type mice (Fig. 5b) . Notably, T FH cells from male CKO mice and those from wild-type mice exhibited similar diversity (Fig. 5b) .
To confirm that the diverse TCR V β repertoire of T FH cells was associated with autoimmunity, we assessed the V β repertoire of wildtype and female CKO Il6 +/− mice. It has been shown that neither of these strains develops disease 19 . We found no difference in repertoire diversity (Fig. 5b) , consistent with their similar number of T FH cells. Thus, the more diverse repertoire was seen only in association with a lupus phenotype.
CTSS inhibitor suppresses lupus development
Given the enhanced activity of CTSS in Blimp-1-deficient DCs and the promising effects of CTSS inhibition on T FH cell differentiation in vitro, we investigated whether inhibition of CTSS would suppress development of the lupus-like phenotype in CKO mice, as has been shown in the MRL/lpr mouse model of lupus 29 . First, we assessed lymphocyte development following long-term treatment with the CTSS inhibitor RO5461111 in chow. Accumulation of the p10 fragment of the invariant chain was seen in splenocytes of wild-type and CKO mice fed RO5461111-treated chow but not in those of mice fed control chow (Fig. 6a) , which demonstrated the efficacy of the treatment. Treatment with RO5461111 did not alter the overall frequency of either lymphocytes or DC subsets in wild-type mice (Fig. 6b) . DC activation, 
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as measured by expression of MHC class II, was also not affected by such treatment (Fig. 6b) . RO5461111 was given to female CKO mice to investigate whether inhibition of CTSS prevented development of the lupus-like phenotype. Splenomegaly was suppressed by inhibition of CTSS, with a reduction in the number of splenocytes in RO5461111-treated CKO mice relative to that in untreated CKO mice (Fig. 6c) . Ciita expression was not altered in splenic DCs in RO5461111-treated CKO mice relative to that in untreated CKO mice (Fig. 6d) . RO5461111-treated CKO mice showed significantly reduced titers of antibodies to double-stranded DNA at both 4 months and 6 months, relative to that in untreated CKO mice (Fig. 6e) . Proteinuria and deposition of IgG in glomeruli were also significantly lower in RO5461111-treated CKO mice than in untreated CKO mice (Fig. 6f,g ).
The frequency of T FH cells and effector memory T cells was significantly lower in RO5461111-treated CKO mice than in untreated CKO mice (~3.5-fold and 2-fold, respectively), while the frequency of naive T cells (CD44 lo CD62L hi ) was slightly higher (~2-fold) in RO5461111-treated CKO mice than in untreated CKO mice (Fig. 7a) . Consistent with the lower frequency of T FH cells, the frequency of germinal-center B cells and plasma cells was also much lower (~10-fold) in RO5461111-treated CKO mice than in untreated CKO mice (Fig. 7b,c) . These data demonstrated that increased CTSS expression promoted the development of a lupus-like phenotype in CKO mice and that inhibition of CTSS activity was able to suppress the development of disease. Finally, the V β repertoire was significantly less diverse in T FH cells from RO5461111-treated CKO mice than in Fig. 1a ) and bottom), are from two independent experiments with n = 5 mice (control) or n = 6 mice (RO5461111) (c,e) or are representative of two experiments with five samples per group (f).
A r t i c l e s those from untreated CKO mice (Fig. 7d) . Thus, higher CTSS expression and activity in DCs led to a T FH cell population with greater TCR diversity.
DISCUSSION
Alterations in antigen presentation can lead to autoimmune or inflammatory diseases 30 . Human genetic studies have shown that genes encoding human leukocyte antigen class II represent prominent risk alleles for autoimmune diseases, including SLE 31, 32 . As human leukocyte antigens are critical in establishing thresholds for the selection and activation of T cells, the TCR repertoire has been presumed to be a key contributor to many autoimmune diseases 33 .
A role for Blimp-1 in antigen presentation was initially suggested in a study showing that Blimp-1 regulates expression of Ciita, which encodes a positive regulator of MHC class II expression in B cells 20 . Subsequently, Blimp-1 was shown to regulate MHC class II in DCs and thereby affect the threshold for activation of CD4 + helper T cells in a mouse model of experimental autoimmune encephalomyelitis 34 .
The importance of antigen presentation prompted us to investigate whether Blimp-1 alters antigen presentation to T cells and, thus, the TCR repertoire. Blimp-1-deficient DCs showed altered expression of several genes encoding molecules involved in antigen presentation, including Ctss. Deletion of Blimp-1 led to increased Ctss transcription in DCs because Blimp-1 is a transcriptional repressor of Ctss and of Il6. IL-6 had high expression in Blimp-1-deficient DCs from female mice, which led to increased Ctss expression. Thus, Bimp-1 directly and indirectly regulated Ctss expression. As described in a published study, increased activation of IL-6 and STAT3 also decreases expression of the gene encoding cystatin C, which subsequently enhances CTSS activity 24 . The increased CTSS activity in DCs of female CKO mice led to increased diversity in the TCR repertoire of T FH cells, which was abolished by a CTSS-specific inhibitor. These findings suggested that an increase in CTSS expression associated with absent or low expression of Blimp-1 generated a repertoire more skewed toward self-reactivity. While it is likely that the PRDM1 risk allele for SLE also leads to a more-diverse repertoire of T FH cells, this will require confirmation in studies of human subjects with the risk allele or the non-risk allele.
The importance of appropriate expression of CTSS in antigen presentation is now widely accepted, and its molecular mechanism has been investigated in other studies. Modulation of the expression of CTSS and CTSL has been shown to lead to alterations in the pool of peptides presented by MHC class II molecules in an in vitro study 10, 35 . Thymic DCs express CTSS and efficiently cleave many known autoantigens; when CTSS concentrations are increased, it is presumed those T cell epitopes that mediate negative selection are destroyed, which allows autoreactive T cells to escape to the periphery 12 . Conversely, CTSS-deficient mice are very resistant to the development of experimental autoimmune myasthenia gravis 36 . Our study here has shown that enhanced CTSS in DCs can lead to an alteration of the T cell repertoire in the T FH cell compartment. Notably, increased CTSS has been observed in serum from patients with SLE and lupus nephritis 37 .
An increased frequency of T FH cells in peripheral lymphoid organs is a phenotype commonly observed in animal models of SLE 38, 39 . However, it is not clearly understood whether an increased number of T FH cells results in a predisposition to autoimmunity or whether the antigenic specificity of the T FH cells in these models is also altered. The antigenic specificity of activated CD4 + T cells is determined largely by encounter with peptide-MHC class II complexes on DCs 40, 41 . While TCR selection occurs in the thymus, the differentiation of effector T cells occurs in the periphery when CD4 + T cells encounter APCs presenting specific peptide-MHC class II complexes 42 . We do not yet know whether the more-diverse TCR repertoire of T FH cells observed in female CKO mice than in female wild-type mice was determined by selection in the thymus or activation in the periphery. Nonetheless, this study has demonstrated the importance of the precise regulation of CTSS in APCs in determining the T cell repertoire and the fate of autoreactive T cells. Describe how sample size was determined. Sample size to achieve adequate power was chosen based on our previous studies with similar methods.
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